Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus

Mycoses

Volumn 59, Issue 4, 2016, Pages 198-219

  Gonçalves, Sarah Santos ^a   Souza, Ana Carolina Remondi ^a   Chowdhary, Anuradha ^b   Meis, Jacques F ^c,d   Colombo, Arnaldo Lopes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF DELHI   (India)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amphotericin B; Antifungal resistance; Aspergillus spp.; Azoles; Candida spp.; Echinocandins

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CANDIDA DRUG RESISTANCE 1; CANDIDA DRUG RESISTANCE 2; CHITIN; ECHINOCANDIN; FKS1 PROTEIN; FLUCONAZOLE; PROTEIN; PYRROLE; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASIA; ASPERGILLUS; ASPERGILLUS ALABAMENSIS; ASPERGILLUS ALLILACEUS; ASPERGILLUS CALIDOUSTUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATIAFFINIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS LENTULUS; ASPERGILLUS NIGER; ASPERGILLUS PSEUDOFISHERI; ASPERGILLUS SYDOWII; ASPERGILLUS TERREUS; ASPERGILLUS UDAGAWAE; ASPERGILLUS VERSICOLOR; ASPERGILLUS VIRIDINUTANS; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CHRONIC GRANULOMATOUS DISEASE; CLINICAL PRACTICE; CONFORMATIONAL TRANSITION; DEVELOPED COUNTRY; DRUG MECHANISM; EARLY DIAGNOSIS; ENZYME INHIBITION; ENZYME SYNTHESIS; EUROPE; HUMAN; IN VITRO STUDY; INFECTION CONTROL; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MUTATION; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; RISK FACTOR; ASPERGILLOSIS; DRUG EFFECTS; GLOBAL HEALTH; MICROBIOLOGY; PREVALENCE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; GLOBAL HEALTH; HUMANS; PREVALENCE;

EID: 84960094417     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12469     Document Type: Article

References (330)

1. Magill SS, Edwards JR, Bamberg W et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-208.
2. Garey KW, Aitken SL, Dima-Ala A et al. Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci 2015; 349: 316-20.
3. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-16.
4. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: E343-53.
5. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51: 561-70.
6. Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD. Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. Mycoses 2014; 57: 69-78.
7. Allou N, Allyn J, Montravers P. When and how to cover for fungal infections in patients with severe sepsis and septic shock. Curr Infect Dis Rep 2011; 13: 426-32.
8. Bow EJ, Vanness DJ, Slavin M et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis 2015; 15: 128.
9. Candoni A, Caira M, Cesaro S et al. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses 2014; 57: 342-50.
10. Apisarnthanarak A, Yatrasert A, Mundy LM. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol 2010; 31: 722-7.
11. Valerio M, Munoz P, Rodriguez-Gonzalez C et al. Training should be the first step toward an antifungal stewardship program. Enferm Infecc Microbiol Clin 2015; 33: 221-7.
12. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 2015; 2016(62): 362-8. pii: civ885. [Epub ahead of print].
13. Sanguinetti M, Posteraro B, Lass-Florl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses 2015; 58(SUPPL. 2): 2-13.
14. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med 2015; 5: a019752.
15. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 2011; 15: e759-63.
16. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325-34.
17. Peman J, Canton E, Minana JJ et al. [Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study]. Rev Iberoam Micol 2011; 28: 91-9.
18. Tragiannidis A, Fegeler W, Rellensmann G et al. Candidaemia in a European Paediatric University Hospital: a 10-year observational study. Clin Microbiol Infect 2012; 18: E27-30.
19. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55: 1352-61.
20. Lockhart SR, Iqbal N, Cleveland AA et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 2012; 50: 3435-42.
21. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol 2013; 51: 841-8.
22. Ericsson J, Chryssanthou E, Klingspor L et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect 2013; 19: E218-21.
23. Klingspor L, Tortorano AM, Peman J et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). Clin Microbiol Infect 2015; 21: e1-10.
24. Puig-Asensio M, Padilla B, Garnacho-Montero J et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2014; 20: O245-54.
25. Pfaller MA, Jones RN, Castanheira M. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 2014; 57: 602-11.
26. Pfaller MA, Andes DR, Diekema DJ et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2, 496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS ONE 2014; 9: e101510.
27. Guinea J, Zaragoza O, Escribano P et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 2014; 58: 1529-37.
28. Moretti ML, Trabasso P, Lyra L et al. Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med Mycol 2013; 51: 225-30.
29. Colombo AL, Garnica M, Aranha Camargo LF et al. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med Mycol 2013; 51: 38-44.
30. Colombo AL, Guimaraes T, Sukienik T et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 2014; 40: 1489-98.
31. Omrani AS, Makkawy EA, Baig K et al. Ten-year review of invasive Candida infections ina tertiary care center in Saudi Arabia. Saudi Med J 2014; 35: 821-6.
32. Tan BH, Chakrabarti A, Li RY et al. Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect 2015; 21: 946-53.
33. Cheng YR, Lin LC, Young TG, Liu CE, Chen CH, Tsay RW. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect 2006; 39: 155-61.
34. Chowdhary A, Becker K, Fegeler W et al. An outbreak of candidemia due to Candida tropicalis in a neonatal intensive care unit. Mycoses 2003; 46: 287-92.
35. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol 2010; 59: 873-80.
36. Taj-Aldeen SJ, Kolecka A, Boesten R et al. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection 2014; 42: 393-404.
37. Ellis M, Hedstrom U, Jumaa P, Bener A. Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol 2003; 41: 521-8.
38. Chowdhary A, Sharma C, Duggal S et al. New clonal strain of Candida auris, Delhi. India. Emerg Infect Dis 2013; 19: 1670-3.
39. Chowdhary A, Anil Kumar V, Sharma C et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 2014; 33: 919-26.
40. Kathuria S, Singh PK, Sharma C et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 2015; 53: 1823-30.
41. Sharma C, Kumar N, Meis JF, Pandey R, Chowdhary A. Draft genome sequence of a fluconazole-resistant Candida auris strain from a candidemia patient in India. Genome Announc 2015; pii: e00722-15. doi: 10.1128/genomeA.00722-15.
42. Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon Candida species fungemia among cancer patients, Houston, Texas. USA. Emerg Infect Dis 2015; 21: 1942-50.
43. Minea B, Nastasa V, Moraru RF et al. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis 2015; 34: 367-83.
44. Pinhati HM, Bizerra FC, Siqueira RA, Castro FF, Colombo AL. Outbreak of candidemia due fluconazole resistant Candida parapsilosis strains in a tertiary care hospital in Brazil. Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology: Denver, CO, 2013.
45. Souza AC, Fuchs BB, Pinhati HM et al. Candida parapsilosis resistance to fluconazole: Molecular mechanisms and in vivo impact in infected Galleria mellonella larvae. Antimicrob Agents Chemother 2015; 59: 6581-7.
46. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-95.
47. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol 2010; 48: 1478-80.
48. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4: 625-32.
49. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52: 1244-51.
50. Bastos VR, Santos DW, Padovan AC et al. Early invasive pulmonary aspergillosis in a kidney transplant recipient caused by Aspergillus lentulus: first Brazilian report. Mycopathologia 2015; 179: 299-305.
51. Barchiesi F, Mazzocato S, Mazzanti S et al. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. Liver Transpl 2015; 21: 204-12.
52. Kathuria S, Sharma C, Singh PK et al. Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing. PLoS ONE 2015; 10: e0118997.
53. Azzola A, Passweg JR, Habicht JM et al. Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection. J Clin Microbiol 2004; 42: 4805-8.
54. Goncalves SS, Stchigel AM, Cano J, Guarro J, Colombo AL. In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi. Antimicrob Agents Chemother 2013; 57: 1944-7.
55. Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 2011; 54: e583-9.
56. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49(SUPPL. 1): S90-5.
57. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 2013; 9: e1003633.
58. Paul RA, Rudramurthy SM, Meis JF, Mouton JW, Chakrabarti A. A novel Y319H substitution in Cyp51C associated with azole resistance in Aspergillus flavus. Antimicrob Agents Chemother 2015; 59: 6615-9.
59. Arendrup MC, Jensen RH, Grif K et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51A M217I alteration. J Infect Dis 2012; 206: 981-5.
60. Pfaller MA, Messer SA, Boyken L et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46: 2568-72.
61. Pham CD, Reiss E, Hagen F, Meis JF, Lockhart SR. Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis 2014; 20: 1498-503.
62. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011; 89: 864-72.
63. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-904.
64. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E et al. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 2014; 69: 1533-6.
65. Alastruey-Izquierdo A, Mellado E, Pelaez T et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013; 57: 3380-7.
66. Baddley JW, Marr KA, Andes DR et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3271-5.
67. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
68. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
69. Bueid A, Howard SJ, Moore CB et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-8.
70. Schweer KE, Bangard C, Hekmat K, Cornely OA. Chronic pulmonary aspergillosis. Mycoses 2014; 57: 257-70.
71. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002; 40: 2648-50.
72. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011; 17: 1846-54.
73. van der Linden JW, Camps SM, Kampinga GA et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-20.
74. van Ingen J, van der Lee HA, Rijs TA et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. J Antimicrob Chemother 2015; 70: 178-81.
75. Fuhren J, Voskuil WS, Boel CH et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother 2015; 70: 2894-8.
76. Tashiro M, Izumikawa K, Hirano K et al. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother 2012; 56: 4870-5.
77. Negri CE, Goncalves SS, Xafranski H et al. Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles. J Clin Microbiol 2014; 52: 3633-40.
78. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012; 67: 362-6.
79. 34/L98H mutations in the cyp51A gene in India. PLoS ONE 2012; 7: e52871.
80. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol 2015; 6: 428.
81. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55: 4465-8.
82. Tashiro M, Izumikawa K, Minematsu A et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki. Japan. Antimicrob Agents Chemother 2012; 56: 584-7.
83. Seyedmousavi S, Hashemi SJ, Zibafar E et al. Azole-resistant Aspergillus fumigatus. Iran. Emerg Infect Dis 2013; 19: 832-4.
84. Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. J Antimicrob Chemother 2015; 70: 412-5.
85. Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr Top Med Mycol 1985; 1: 313-51.
86. Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 2014; 44: 1315-32.
87. Parker JE, Warrilow AG, Price CL, Mullins JG, Kelly DE, Kelly SL. Resistance to antifungals that target CYP51. J Chem Biol 2014; 7: 143-61.
88. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-16.
89. Sanglard D, Coste A, Ferrari S. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 2009; 9: 1029-50.
90. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-5.
91. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86.
92. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482-7.
93. Goldman GH, da Silva Ferreira ME, dos Reis Marques E et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004; 50: 25-32.
94. Hu L, Du X, Li T et al. Genetic and phenotypic characterization of Candida albicans strains isolated from infectious disease patients in Shanghai. J Med Microbiol 2015; 64: 74-83.
95. Moran GP, Sanglard D, Donnelly SM, Shanley DB, Sullivan DJ, Coleman DC. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 1998; 42: 1819-30.
96. Sanglard D, Ischer F, Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 2001; 45: 1174-83.
97. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43: 2753-65.
98. Katiyar SK, Edlind TD. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol 2001; 39: 109-16.
99. Pinjon E, Moran GP, Jackson CJ et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 2003; 47: 2424-37.
100. Torelli R, Posteraro B, Ferrari S et al. The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol 2008; 68: 186-201.
101. Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD. Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell 2011; 10: 373-83.
102. Miyazaki H, Miyazaki Y, Geber A et al. Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob Agents Chemother 1998; 42: 1695-701.
103. Barchiesi F, Calabrese D, Sanglard D et al. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 2000; 44: 1578-84.
104. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother 2005; 49: 4608-15.
105. Jiang C, Dong D, Yu B et al. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother 2013; 68: 778-85.
106. Silva AP, Miranda IM, Guida A et al. Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob Agents Chemother 2011; 55: 3546-56.
107. Sellam A, Tebbji F, Nantel A. Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. Eukaryot Cell 2009; 8: 1174-83.
108. Chen CG, Yang YL, Shih HI, Su CL, Lo HJ. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother 2004; 48: 4505-12.
109. Pao SS, Paulsen IT, Saier MH Jr. Major facilitator superfamily. Microbiol Mol Biol Rev 1998; 62: 1-34.
110. Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R, Rogers PD. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 2007; 3: e164.
111. Dunkel N, Blass J, Rogers PD, Morschhauser J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol 2008; 69: 827-40.
112. Schubert S, Rogers PD, Morschhauser J. Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob Agents Chemother 2008; 52: 4274-80.
113. Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother 2015; 59: 1030-7.
114. Wirsching S, Michel S, Morschhauser J. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 2000; 36: 856-65.
115. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhauser J. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother 2001; 45: 3416-21.
116. Fuentes M, Hermosilla G, Alburquenque C, Falconer MA, Amaro J, Tapia C. [Characterization of azole resistance mechanisms in Chilean clinical isolates of Candida albicans]. Rev Chilena Infectol 2014; 31: 511-7.
117. Moran G, Sullivan D, Morschhauser J, Coleman D. The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance. Antimicrob Agents Chemother 2002; 46: 2829-41.
118. Rajendran R, Mowat E, McCulloch E et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother 2011; 55: 2092-7.
119. Ferreira ME, Colombo AL, Paulsen I et al. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med Mycol 2005; 43(SUPPL. 1): S313-9.
120. Slaven JW, Anderson MJ, Sanglard D et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol 2002; 36: 199-206.
121. da Silva Ferreira ME, Malavazi I, Savoldi M et al. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet 2006; 50: 32-44.
122. Fraczek MG, Bromley M, Buied A et al. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2013; 68: 1486-96.
123. Monk BC, Tomasiak TM, Keniya MV et al. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci USA 2014; 111: 3865-70.
124. Snelders E, Karawajczyk A, Verhoeven RJ et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol 2011; 48: 1062-70.
125. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 2010; 66: 373-84.
126. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48: 2124-31.
127. Kakeya H, Miyazaki Y, Miyazaki H, Nyswaner K, Grimberg B, Bennett JE. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 2000; 44: 2985-90.
128. Lamb DC, Kelly DE, White TC, Kelly SL. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 2000; 44: 63-7.
129. Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 1997; 151: 263-8.
130. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-53.
131. Perea S, Lopez-Ribot JL, Wickes BL et al. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 1695-703.
132. Forastiero A, Mesa-Arango AC, Alastruey-Izquierdo A et al. Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother 2013; 57: 4769-81.
133. Ricardo E, Miranda IM, Faria-Ramos I, Silva RM, Rodrigues AG, Pina-Vaz C. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. Antimicrob Agents Chemother 2014; 58: 4604-11.
134. Couzigou C, Gabriel F, Biteau N, Fitton-Ouhabi V, Noel T, Accoceberry I. Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of Candida kefyr recovered from a stem cell transplant patient for acute myeloid leukemia. Med Mycol Case Rep 2014; 5: 12-5.
135. Hull CM, Parker JE, Bader O et al. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother 2012; 56: 4223-32.
136. Mellado E, Garcia-Effron G, Buitrago MJ, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob Agents Chemother 2005; 49: 2536-8.
137. Hu W, Sillaots S, Lemieux S et al. Essential gene identification and drug target prioritization in Aspergillus fumigatus. PLoS Pathog 2007; 3: e24.
138. Rodriguez-Tudela JL, Alcazar-Fuoli L, Cuesta I et al. Clinical relevance of resistance to antifungals. Int J Antimicrob Agents 2008; 32(SUPPL. 2): S111-3.
139. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004; 48: 2747-50.
140. Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-9.
141. Bader O, Weig M, Reichard U et al. cyp51A-Based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 2013; 57: 3513-7.
142. Becher R, Wirsel SG. Fungal cytochrome P450 sterol 14alpha-demethylase (CYP51) and azole resistance in plant and human pathogens. Appl Microbiol Biotechnol 2012; 95: 825-40.
143. Alcazar-Fuoli L, Mellado E. Current status of antifungal resistance and its impact on clinical practice. Br J Haematol 2014; 166: 471-84.
144. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 2013; 26: 493-500.
145. Paul S, Moye-Rowley WS. Multidrug resistance in fungi: regulation of transporter-encoding gene expression. Front Physiol 2014; 5: 143.
146. Kidd SE, Goeman E, Meis JF, Slavin MA, Verweij PE. Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 2015; 58: 350-5.
147. 34/L98H mutations in Taiwan. Mycoses 2015; 58: 544-9.
148. Asano M, Kano R, Makimura K, Hasegawa A, Kamata H. Molecular typing and in-vitro activity of azoles against clinical isolates of Aspergillus fumigatus and A. niger in Japan. J Infect Chemother 2011; 17: 483-6.
149. Hagiwara D, Takahashi H, Watanabe A et al. Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis. J Clin Microbiol 2014; 52: 4202-9.
150. Abdolrasouli A, Rhodes J, Beale MA et al. Genomic context of azole resistance mutations in Aspergillus fumigatus determined using whole-genome sequencing. MBio 2015; 6: e00536. doi:10.1128/mBio.00536-15.
151. Astvad KM, Jensen RH, Hassan TM et al. First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother 2014; 58: 5096-101.
152. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 2014; 69: 555-7.
153. Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol 2014; 9: 697-711.
154. Chen Y, Wang H, Lu Z et al. Emergence of TR46/Y121F/T289A in an Aspergillus fumigatus isolate from a Chinese patient. Antimicrob Agents Chemother 2015; 59: 7148-50.
155. Pelaez T, Monteiro MC, Garcia-Rubio R, Bouza E, Gomez-Lopez A, Mellado E. First detection of Aspergillus fumigatus azole-resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. New Microbes New Infect 2015; 6: 33-4.
156. Lavergne RA, Morio F, Favennec L et al. First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. Antimicrob Agents Chemother 2015; 59: 4331-5.
157. Steinmann J, Hamprecht A, Vehreschild MJ et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015; 70: 1522-6.
158. Le Pape P, Lavergne RA, Morio F, Alvarez C. Multiple fungicide-driven alterations in azole-resistant Aspergillus fumigatus, Colombia, 2015. Emerg Infect Dis 2016; 22: 156-7. in press. http://dx.doi.org/10.3201/eid2201.1510978.
159. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 2009; 47: 217-20.
160. Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240-8.
161. Redding SW, Kirkpatrick WR, Coco BJ et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 2002; 40: 1879-81.
162. Rogers PD, Vermitsky JP, Edlind TD, Hilliard GM. Proteomic analysis of experimentally induced azole resistance in Candida glabrata. J Antimicrob Chemother 2006; 58: 434-8.
163. Tavakoli M, Zaini F, Kordbacheh M, Safara M, Raoofian R, Heidari M. Upregulation of the ERG11 gene in Candida krusei by azoles. Daru 2010; 18: 276-80.
164. Blatzer M, Barker BM, Willger SD et al. SREBP coordinates iron and ergosterol homeostasis to mediate triazole drug and hypoxia responses in the human fungal pathogen Aspergillus fumigatus. PLoS Genet 2011; 7: e1002374.
165. Moye-Rowley WS. Multiple mechanisms contribute to the development of clinically significant azole resistance in Aspergillus fumigatus. Front Microbiol 2015; 6: 70.
166. Willger SD, Puttikamonkul S, Kim KH et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog 2008; 4: e1000200.
167. Camps SM, van der Linden JW, Li Y et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56: 10-6.
168. Tuncher A, Sprote P, Gehrke A, Brakhage AA. The CCAAT-binding complex of eukaryotes: evolution of a second NLS in the HapB subunit of the filamentous fungus Aspergillus nidulans despite functional conservation at the molecular level between yeast, A.nidulans and human. J Mol Biol 2005; 352: 517-33.
169. Ben-Ami R, Olshtain-Pops K, Krieger M et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012; 56: 2518-23.
170. Mikulska M, Del Bono V, Ratto S, Viscoli C. Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol 2012; 8: 755-65.
171. Lortholary O, Renaudat C, Sitbon K et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014; 40: 1303-12.
172. Schuster MG, Meibohm A, Lloyd L, Strom B. Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. J Infect 2013; 66: 278-84.
173. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54: 3149-54.
174. Cuervo G, Puig-Asensio M, Garcia-Vidal C et al. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. Clin Microbiol Infect 2015; 21: e1-9.
175. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-14.
176. Moore CB, Sayers N, Mosquera J, Slaven J, Denning DW. Antifungal drug resistance in Aspergillus. J Infect 2000; 41: 203-20.
177. Mortensen KL, Jensen RH, Johansen HK et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49: 2243-51.
178. Howard SJ, Pasqualotto AC, Anderson MJ et al. Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 2013; 56: 434-41.
179. Snelders E, Melchers WJ, Verweij PE. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol 2011; 6: 335-47.
180. Badali H, Vaezi A, Haghani I et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses 2013; 56: 659-63.
181. Camps SM, Rijs AJ, Klaassen CH et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 2012; 50: 2674-80.
182. Hamprecht A, Buchheidt D, Vehreschild JJ et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012; 17: 20262.
183. Burgel PR, Baixench MT, Amsellem M et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012; 56: 869-74.
184. Stensvold RC, Jørgensen LN, Arendrup MC. Azole-resistant invasive aspergillosis: relationship to agriculture. Curr Fung Infect Rep 2012; 6: 178-91.
185. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-57.
186. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm 2006; 63: 1813-20.
187. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171-8.
188. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
189. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-81.
190. Colombo AL, Guimaraes T, Camargo LF et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis 2013; 17: 283-312.
191. Fekkar A, Dannaoui E, Meyer I et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis 2014; 33: 1489-96.
192. Cleveland AA, Harrison LH, Farley MM et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE 2015; 10: e0120452.
193. Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 2014; 40: 1241-55.
194. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-32.
195. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 2014; 27: 484-92.
196. Bizerra FC, Jimenez-Ortigosa C, Souza AC et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother 2014; 58: 2438-40.
197. Arendrup MC. Invasive fungal infections: past achievements and challenges ahead. Clin Microbiol Infect 2009; 15: 599-601.
198. Marr KA, Schlamm HT, Herbrecht R et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-9.
199. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
200. Staab JF, Kahn JN, Marr KA. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother 2010; 54: 4992-8.
201. Eschertzhuber S, Velik-Salchner C, Hoermann C, Hoefer D, Lass-Florl C. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl Infect Dis 2008; 10: 190-2.
202. Barchiesi F, Spreghini E, Tomassetti S et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719-27.
203. Kahn JN, Hsu MJ, Racine F, Giacobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1, 3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50: 2214-6.
204. Enache-Angoulvant A, Girard A, Poirot JL, Hennequin C. In vitro activity of caspofungin and voriconazole against uncommon Candida spp. Int J Antimicrob Agents 2009; 33: 595-6.
205. Mazur P, Morin N, Baginsky W et al. Differential expression and function of two homologous subunits of yeast 1, 3-beta-D-glucan synthase. Mol Cell Biol 1995; 15: 5671-81.
206. Ishihara S, Hirata A, Nogami S, Beauvais A, Latge JP, Ohya Y. Homologous subunits of 1, 3-beta-glucan synthase are important for spore wall assembly in Saccharomyces cerevisiae. Eukaryot Cell 2007; 6: 143-56.
207. Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother 2012; 56: 6304-9.
208. Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol 2011; 6: 441-57.
209. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-63.
210. Garcia-Effron G, Chua DJ, Tomada JR et al. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 2010; 54: 2225-7.
211. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
212. Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol 2010; 47: 117-26.
213. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
214. Desnos-Ollivier M, Bretagne S, Raoux D et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother 2008; 52: 3092-8.
215. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18: 86-90.
216. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-12.
217. Jensen RH, Johansen HK, Arendrup MC. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 2013; 57: 614-7.
218. Pham CD, Iqbal N, Bolden CB et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58: 4690-6.
219. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52: 2263-5.
220. Thompson GR 3rd, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS, Patterson TF. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008; 52: 3783-5.
221. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-4.
222. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
223. Pfaller MA, Boyken L, Hollis RJ et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48: 52-6.
224. Tortorano AM, Prigitano A, Lazzarini C et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 2013; 41: 655-62.
225. Colombo AL, Ngai AL, Bourque M et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010; 54: 1864-71.
226. Foldi R, Kovacs R, Gesztelyi R et al. Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia 2012; 174: 311-8.
227. Spreghini E, Orlando F, Tavanti A et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother 2012; 67: 2195-202.
228. Szilagyi J, Foldi R, Gesztelyi R et al. Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model. Chemotherapy 2012; 58: 159-64.
229. Fernandez-Ruiz M, Aguado JM, Almirante B et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis 2014; 58: 1413-21.
230. Arendrup MC, Perkhofer S, Howard SJ et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-11.
231. Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1185-93.
232. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005; 43(SUPPL. 1): S299-305.
233. Rocha EM, Garcia-Effron G, Park S, Perlin DS. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 4174-6.
234. Imhof A, Balajee SA, Marr KA. New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol 2003; 41: 5683-8.
235. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 2008; 4: e1000040.
236. Plaine A, Walker L, Da Costa G et al. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol 2008; 45: 1404-14.
237. Walker LA, Gow NA, Munro CA. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother 2013; 57: 146-54.
238. Cota JM, Grabinski JL, Talbert RL et al. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother 2008; 52: 1144-6.
239. Blanchard E, Lortholary O, Boukris-Sitbon K et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother 2011; 55: 5358-61.
240. Lortholary O, Desnos-Ollivier M, Sitbon K et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2, 441 patients. Antimicrob Agents Chemother 2011; 55: 532-8.
241. Shields RK, Nguyen MH, Press EG et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012; 56: 4862-9.
242. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014; 59: 819-25.
243. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 2014; 20: 1833-40.
244. Ruggero MA, Topal JE. Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy. Transpl Infect Dis 2014; 16: 469-72.
245. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50: 291-322.
246. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807-25.
247. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
248. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272-9.
249. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550-63.
250. Mesa-Arango AC, Trevijano-Contador N, Roman E et al. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother 2014; 58: 6627-38.
251. Peman J, Canton E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 2009; 7: 453-60.
252. Mohr JF, Hall AC, Ericsson CD, Ostrosky-Zeichner L. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. Pharmacotherapy 2005; 25: 426-8.
253. Wang YH, Zhang JP, Chang Y, Hu CQ. A newly identified derivative of amphotericin B: isolation, structure determination and primary evaluation of the activity and toxicity. J Antibiot (Tokyo) 2010; 63: 553-7.
254. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
255. Falci DR, da Rosa FB, Pasqualotto AC. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. Mycoses 2015; 58: 104-12.
256. Falci DR, da Rosa FB, Pasqualotto AC. Hematological toxicities associated with amphotericin B formulations. Leuk Lymphoma 2015; 56: 2889-94.
257. Groll AH, Muller FM, Piscitelli SC, Walsh TJ. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998; 210: 264-73.
258. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
259. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
260. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996; 173: 1208-15.
261. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002; 35: 891-5.
262. da Matta DA, de Almeida LP, Machado AM et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis 2007; 57: 399-404.
263. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
264. Nolte FS, Parkinson T, Falconer DJ et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41: 196-9.
265. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999; 43: 1289-90.
266. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938-44.
267. Favel A, Michel-Nguyen A, Peyron F et al. Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature. Diagn Microbiol Infect Dis 2003; 47: 331-9.
268. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4, 936 clinical isolates of Candida species. J Clin Microbiol 2004; 42: 4977-9.
269. Zaoutis TE, Foraker E, McGowan KL et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005; 52: 295-8.
270. Chen SC, Marriott D, Playford EG et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009; 15: 662-9.
271. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global sntifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
272. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 2008; 46: 541-6.
273. Merz WG. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984; 20: 1194-5.
274. Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis 2001; 32: 186-90.
275. Moosa MY, Alangaden GJ, Manavathu E, Chandrasekar PH. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. J Antimicrob Chemother 2002; 49: 209-13.
276. Steinbach WJ, Benjamin DK, Kontoyiannis DP et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-8.
277. Hadrich I, Makni F, Neji S et al. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Med Mycol 2012; 50: 829-34.
278. Guinea J, Pelaez T, Alcala L, Ruiz-Serrano MJ, Bouza E. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob Agents Chemother 2005; 49: 3495-7.
279. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6.
280. Lass-Florl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-7.
281. Lass-Florl C, Kofler G, Kropshofer G et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497-502.
282. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47: 2404-12.
283. Young LY, Hull CM, Heitman J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother 2003; 47: 2717-24.
284. Vandeputte P, Tronchin G, Berges T, Hennequin C, Chabasse D, Bouchara JP. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Chemother 2007; 51: 982-90.
285. Vandeputte P, Tronchin G, Larcher G et al. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob Agents Chemother 2008; 52: 3701-9.
286. Martel CM, Parker JE, Bader O et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother 2010; 54: 3578-83.
287. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8: 344-58.
288. Blum G, Perkhofer S, Grif K et al. A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates. Clin Microbiol Infect 2008; 14: 1146-51.
289. Blatzer M, Jukic E, Posch W et al. Amphotericin B resistance in Aspergillus terreus is overpowered by coapplication of pro-oxidants. Antioxid Redox Signal 2015; 23: 1424-38.
290. Nucci M, Queiroz-Telles F, Alvarado-Matute T et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS ONE 2013; 8: e59373.
291. Cordoba S, Vivot W, Bosco-Borgeat ME et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol 2011; 43: 176-85.
292. Silva V, Diaz MC, Febre N. Chilean Invasive Fungal Infections G. Invasive fungal infections in Chile: a multicenter study of fungal prevalence and susceptibility during a 1-year period. Med Mycol 2004; 42: 333-9.
293. Dolande Franco ME, Reviakina V, Panizo MM et al. Distribution and antifungal susceptibility of Candida clinical isolations coming from six health care centers in the metropolitan area of Caracas, Venezuela (years 2003-2005). Rev Iberoam Micol 2008; 25: 17-21.
294. Cortes JA, Reyes P, Gomez CH et al. Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogota. Colombia. Braz J Infect Dis 2014; 18: 631-7.
295. Corzo-Leon DE, Alvarado-Matute T, Colombo AL et al. Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. PLoS ONE 2014; 9: e97325.
296. Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 2005; 9: 411-8.
297. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-23.
298. Bruder-Nascimento A, Camargo CH, Sugizaki MF et al. Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital. BMC Res Notes 2010; 3: 1.
299. Santos ER, Dal Forno CF, Hernandez MG et al. Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. Rev Inst Med Trop Sao Paulo 2014; 56: 477-82.
300. da Costa VG, Quesada RM, Abe AT, Furlaneto-Maia L, Furlaneto MC. Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey. Mycopathologia 2014; 178: 243-50.
301. Hong SB, Shin HD, Hong J et al. New taxa of Neosartorya and Aspergillus in Aspergillus section Fumigati. Antonie Van Leeuwenhoek 2008; 93: 87-98.
302. Balajee SA, Kano R, Baddley JW et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3138-41.
303. Montenegro G, Sanchez Puch S, Jewtuchowicz VM et al. Phenotypic and genotypic characterization of Aspergillus lentulus and Aspergillus fumigatus isolates in a patient with probable invasive aspergillosis. J Med Microbiol 2009; 58: 391-5.
304. Alhambra A, Catalan M, Moragues MD et al. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Micol 2008; 25: 246-9.
305. Vinh DC, Shea YR, Sugui JA et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49: 102-11.
306. Sugui JA, Vinh DC, Nardone G et al. Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J Clin Microbiol 2010; 48: 220-8.
307. Balajee SA, Marr KA. Phenotypic and genotypic identification of human pathogenic aspergilli. Future Microbiol 2006; 1: 435-45.
308. Vinh DC, Shea YR, Jones PA, Freeman AF, Zelazny A, Holland SM. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009; 15: 1292-4.
309. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses 2009; 52: 206-22.
310. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003; 47: 3085-8.
311. Hsueh PR, Lau YJ, Chuang YC et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005; 49: 512-7.
312. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52: 15-20.
313. Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol 2002; 46: 945-7.
314. Johnson EM, Oakley KL, Radford SA et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85-93.
315. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77: 345-54.
316. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002; 45: 406-7.
317. Verweij PE, Varga J, Houbraken J et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis 2008; 14: 566-72.
318. Lass-Florl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53: 794-5.
319. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-5.
320. Caston JJ, Linares MJ, Gallego C et al. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi. Chest 2007; 131: 230-6.
321. Hachem RY, Kontoyiannis DP, Boktour MR et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-600.
322. Balajee SA, Baddley JW, Peterson SW et al. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot Cell 2009; 8: 713-22.
323. Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 2007; 50: 447-50.
324. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother 2009; 53: 4514-7.
325. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(SUPPL. 1): S49-58.
326. Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell 2008; 7: 630-8.
327. Houbraken J, Due M, Varga J, Meijer M, Frisvad JC, Samson RA. Polyphasic taxonomy of Aspergillus section Usti. Stud Mycol 2007; 59: 107-28.
328. Takahata Y, Hiruma M, Sugita T, Muto M. A case of onychomycosis due to Aspergillus sydowii diagnosed using DNA sequence analysis. Mycoses 2008; 51: 170-3.
329. Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother 2013; 57: 2815-20.
330. Alanio A, Sitterle E, Liance M et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66: 371-4.